|
VEZF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.7303003474467E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.95220000060093E-08 |
| Normal-vs-Stage2 |
3.52900000000211E-05 |
| Normal-vs-Stage3 |
3.44150041797775E-10 |
| Normal-vs-Stage4 |
2.50010001590084E-09 |
| Stage1-vs-Stage2 |
7.966200E-01 |
| Stage1-vs-Stage3 |
1.808150E-01 |
| Stage1-vs-Stage4 |
5.838100E-02 |
| Stage2-vs-Stage3 |
5.748200E-01 |
| Stage2-vs-Stage4 |
3.209400E-01 |
| Stage3-vs-Stage4 |
5.414800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.17279996614661E-10 |
| Normal-vs-AfricanAmerican |
1.104100E-02 |
| Normal-vs-Asian |
1.168850E-04 |
| Caucasian-vs-AfricanAmerican |
1.975650E-01 |
| Caucasian-vs-Asian |
4.281800E-01 |
| AfricanAmerican-vs-Asian |
5.593400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.35510491716673E-11 |
| Normal-vs-Female |
9.60659995996593E-09 |
| Male-vs-Female |
4.886400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.81289999970858E-07 |
| Normal-vs-Age(41-60Yrs) |
6.25670004694712E-09 |
| Normal-vs-Age(61-80Yrs) |
1.80950032735439E-10 |
| Normal-vs-Age(81-100Yrs) |
3.002300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.873000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.439800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.522600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.070800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.089800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.536600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.882800E-03 |
| Classical-VS-Follicular |
3.380100E-04 |
| Classical-VS-Other |
9.747900E-02 |
| Classical-VS-Normal |
2.1615000000974E-07 |
| Tall-VS-Follicular |
7.864200E-01 |
| Tall-VS-Other |
5.136000E-01 |
| Tall-VS-Normal |
2.31469999834033E-08 |
| Follicular-VS-Other |
6.738200E-01 |
| Follicular-VS-Normal |
2.77669998105523E-10 |
| Other-VS-Normal |
1.383410E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.72459999006713E-09 |
| Normal-vs-N1 |
1.21940000319398E-08 |
| N0-vs-N1 |
3.095600E-01 |
|
|
